Memphasys : Presentation at Pitt St Research conference

r personal use only

Creating novel fertility solutions

March 2022

Alison Coutts

Executive Chairman, Memphasys Limited

1

Disclaimer

onlyThis presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should

usenot be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them.

personalThis presentation does not take into consideration the investment objectives, financial situation or particular

eeds of any particular investor.

r

To the fullest extent permitted by law, Memphasys and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this presentation.

2

Memphasys Investment Proposition

only	Memphasys is a medtech company (ASX: MEM) focused on reproductive
	biotechnology
	Developing high value product portfolio (devices, diagnostics and media
	products) addressing major global human and animal reproductive
use	markets
Source of new product pipeline: global Fertility Expert, Laureate Professor
	John Aitken and his research team at University of Newcastle ("UoN")
	MEM employs Professor Aitken part time, supports 7 UoN researchers
	and has a commercially attractive licensing agreement with UoN for
personalr	new discoveries
MEM team of engineers and scientists "productises" the discoveries
Ability to develop the more technically challenging pipeline projects
	will be established within next six months
	Most advanced product: The FelixTM device, co-developed by Professor
	John Aitken with MEM for sperm separation in human IVF
	Important milestone reached with first salesof two FelixTM devices

John Aitken, global leader in reproductive biology:

• published over 650 research articles
• work cited ~55,000 times (h-index of 120, highest citation index in his field and in the top 5% for all of Biology and Biochemistry).
• ranked #1 in the world in sperm biology and fertilisation (Source: Expertscape.com).
• Life work is source of MEM's new product ideas

3

r personal use only

Memphasys Core Product Development Pipeline

							Technical	Addressable	Development
	Product	Initial target use	complexity	stage
	market
							(High/ Low)	(POC = proof of concept)
1 Felix device (sperm separator for IVF)						High	Niche	Initial sales;
					Large	Clinical trials
2	"SODA"						High	Large	Early;
(rapid in situ oxidative stress diagnostic)						Diverse			biochemistry evaluations
3	"SAMSON"
(rapid in situ diagnostic)
a) Total motile sperm count indicator						Low	Niche	POC
					Large
b) Pregnancy predictor						High	Niche	POC

• "SEMPORT"
  (For ambient temperature semen storage and transport)

a)	Quality analysis for remotely provided semen sample				Low	Niche	POC
b)	For AI (without freezing sperm or prior to "sex sorting"				Low	Large	Early;
	process)						concept developed

• Cryopreservation

Retrieval of cryopreserved sperm for IVF				Low	Niche	POC
Improved cryopreservation methods				High	Large	Early;
			Initial concepts developed
2/03/2022						4

Human IVF market

•	IVF use is accelerating, but IVF's success rate remains
only•	stubbornly low
Average of 2.2 IVF cycles before success, averaged
	for all women <40yo
•	IVF slightly increases risk of miscarriage and genetic

Fresh IVF Cycles (millions)

5

4

3

2	1.85	2.02

1

0

Fresh IVF Cycles

(Millions)

			3.28
		2.68	2.96
	2.46
2.24

3.9

3.54

	impairment of offspring
• Male fertility rates in global decline
use	~50% of infertility cases attributed to the male
•
• Sperm separation for IVF is currently based on multi
r personal	step laboratory techniques, DGC or Swim up
• No meaningful advances in sperm preparation &
selection for IVF since the advent of IVF ~40 years ago

	18	19	20	21	22	23	24	25	26
					Year
	Market Value Fresh IVF Cycles
	19		(US $ Billions)
Billions)	17								17.6
							16
15
(US$						14.6
13					13.3
Value
				12
11			11
Market
		10
9	8.7
7.9
	7
	18	19	20	21	22	23	24	25	26
					Year
									5